High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• T-cell prolymphocytic leukemia (T-PLL) is an aggressive hematologic malignancy.
• T-PLL exhibits resistance to conventional chemotherapy, leading to poor prognoses.
• The human CD52 antibody, CAMPATH-1H, was investigated for its therapeutic potential in T-PLL.

Observation:

• Thirty-nine patients with T-PLL, most with prior treatment failures, received CAMPATH-1H.
• CAMPATH-1H was administered intravenously three times weekly until maximal response.
• Prior therapies, including pentostatin, had not resulted in complete remission for most patients.

Findings:

• An overall response rate of 76% was observed, with 60% achieving complete remission (CR) and 16% partial remission (PR).
• Responses were durable, with a median disease-free interval of 7 months.
• Survival was significantly improved in patients achieving CR compared to PR or no response.

Implications:

• CAMPATH-1H demonstrates considerable efficacy as a treatment for T-cell prolymphocytic leukemia.
• Stem cell transplantation may serve as a valuable consolidation strategy following CAMPATH-1H therapy.
• Further studies are warranted to explore the combined use of CAMPATH-1H and stem cell transplantation in T-PLL management.